LCLC-103H（人大細(xì)胞肺癌）
CBP60047
詢(xún) 價(jià)
索取STR
產(chǎn)品描述
產(chǎn)品數(shù)據(jù)庫(kù)
| I. General information | |
| Synonyms: | LCLC-103H |
| Background: | established from the pleural effusion of a 61-year-old Caucasian man with large cell lung carcinoma with giant cells who had received chemo- and radiotherapy; described in the literature to be PAS negative, to exhibit remarkable stroma formation and to overexpress the proto-oncogene MYC |
| Species: | human (Homo sapiens) |
| Tissue: | lung |
| Disease: | large cell lung carcinoma |
| Gender: | N/A |
| Morphology: | pleomorphic, gigantic, adherent cells growing as monolayer; image |
| Growth Mode: | N/A |
| Doubling Time: | ca. 40 hours |
| DNA Profile: | N/A Our Cell Line Authentication Service |
| Culture Medium: |
RPMI-1640+10%FBS LCLC-103H完全培養(yǎng)基，# CBP60047M |
| Cryopreservation medium: | 90%FBS+10%DMSO |
| Virus | ELISA: reverse transcriptase negative; PCR: EBV -, HBV -, HCV -, HHV-8 -, HIV-1 -, HIV-2 -, HTLV-I/II -, MLV -, SMRV - |
| Mycoplasma: | negative in DAPI, microbiological culture, RNA hybridization, PCR assays |
| Immunology: | cytokeratin +, cytokeratin-7 -, cytokeratin-8 +, cytokeratin-17 -, cytokeratin-18 +, cytokeratin-19 +, desmin -, endothel -, EpCAM -, GFAP -, neurofilament -, vimentin + |
| Fingerprint: | multiplex PCR of minisatellite markers revealed a unique DNA profile |
| Species: | confirmed as human with IEF of AST, NP |
| Cytogenetics: | human, highly rearranged flat-moded hexaploid/heptaploid karyotype with 4% polyploidy - 130-160<7n>XXY, -X, -Y, -Y, +1, +1, -2, -2, -3, -6, -6, -8, -8, -9, -9, -9, -10, -13, -13, -13, -14, -14, +15, +16, +16, -17, -18, -19, -19, -20, -20, -20, -20, +18-25mar, del(1)(p22.2), add(1)(q11-21), i(1p)x2, add(3)(p23-24)x2, del(5)(q11q15), i(5q)x2, add(5)(p?), add(6)(q11)x2-3, add(7)(q34)x2, del(7)(q22)x2, i(8q), del(9)(p21)x2-3, del(10)(q23-24)x2, der(10;13)(q10;q10)x2, add(11)(q24-25)x2, del(11)(q23)x2, add(13)(p11), add(16)(q24) - variable number of dmin present - resembles published karyotype |
| Comments: | For more information, please contact us (4008-750-250). |
